Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | MAT2A | P31153 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13723813 | 1.00 | SYK (0.46) | SYKARELANEPIK3CAPIM1 | |
| SCHEMBL13723947 | 0.95 | GFER (0.45) | SYKARELANEPIK3CAPIM1 | |
| SCHEMBL7029894 | 0.90 | SYK (0.44) | SYKARELANEPIK3CAPIM1 | |
| SCHEMBL4715449 | 0.87 | SMN1; SMN2 (0.44) | GFER | |
| SCHEMBL17294200 | 0.87 | SYK (0.46) | SYKARELANEPIK3CAPIM1 | |
| SCHEMBL3047808 | 0.85 | SCN9A (0.49) | SYKARELANEPIM1F10 | |
| SCHEMBL15665092 | 0.85 | CNR2 (0.49) | SYKARELANEPIM1MAT2A | |
| SCHEMBL13284534 | 0.85 | CNR2 (0.49) | SYKARELANEPIM1MAT2A | |
| SCHEMBL3347621 | 0.85 | ELANE (0.54) | SYKARELANEPIM1MAT2A | |
| SCHEMBL15665470 | 0.85 | ELANE (0.54) | SYKARELANEPIM1MAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7070629-B2 | Dye composition comprising at least one diaminopyrazole oxidation base, at least one paraphenylenediamine oxidation base comprising a cyclic amino group, and at least one coupler | L'OREAL, S.A. (FR) | 2006-07-04 | — | — | US | claimed |
| US-20040231066-A1 | Dyeing composition comprising a diaminopyrazole-type oxidation base, a paraphenylenediamine-type oxidation base with cyclic amino group and a coupling agent | L'OREAL S.A. (FR) | 2004-11-25 | — | — | US | claimed |
| EP-1432389-A1 | DYEING COMPOSITION COMPRISING A DIAMINOPYRAZOLE-TYPE OXIDATION BASE, A PARAPHENYLENEDIAMINE-TYPE OXIDATION BASE WITH CYCLIC AMINO GROUP AND A COUPLING AGENT | L'OREAL (FR) | 2004-06-30 | — | — | EP | claimed |
| WO-2003028689-A1 | DYEING COMPOSITION COMPRISING A DIAMINOPYRAZOLE-TYPE OXIDATION BASE, A PARAPHENYLENEDIAMINE-TYPE OXIDATION BASE WITH CYCLIC AMINO GROUP AND A COUPLING AGENT | L'OREAL (FR) | 2003-04-10 | — | — | WO | claimed |
| EP-0937713-B1 | N-(4-Aminophenyl) prolineamide in oxidative hair dye system | BRISTOL MYERS SQUIBB CO (US) | 2001-10-17 | — | — | EP | claimed |
| JP-11269143-A | — | — | None | — | — | JP | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20160303138-A1 | Combination Therapy Of Substituted Oxazolidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| EP-1149576-A1 | Oxidative dyeing composition for keratinic fibres comprising 1-(4-aminophenyl)pyrrolidine and a sugar-based polymer | L'OREAL (FR) | 2001-10-31 | — | — | EP | disclosed |
| EP-1149575-A1 | Oxidative dyeing composition for keratin fibres comprising 1-(4-aminophenyl)-pyrrolidine and a particular direct dye | L'OREAL (FR) | 2001-10-31 | — | — | EP | disclosed |
| EP-1147763-A1 | Oxidative dyeing composition for keratinic fibres containing 1-(4-aminophenyl)-pyrrolidine and an enzymatic oxidation system | L'OREAL (FR) | 2001-10-24 | — | — | EP | disclosed |
| EP-0937713-B1 | N-(4-Aminophenyl) prolineamide in oxidative hair dye system | BRISTOL MYERS SQUIBB CO (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001047919-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
| JP-H11269143-A | N-(4-AMINOPHENYL)PROLINEAMIDE, ITS USE AND COMPOSITION CONTAINING THE SAME | BRISTOL MYERS SQUIBB CO | 1999-10-05 | — | — | JP | disclosed |
| EP-0937713-A1 | N-(4-Aminophenyl) prolineamide in oxidative hair dye system | Bristol-Myers Squibb Company (US) | 1999-08-25 | — | — | EP | disclosed |
| US-5876464-A | AQUEOUS SOLUTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040231066-A1 | Dyeing composition comprising a diaminopyrazole-type oxidation base, a paraphenylenediamine-type oxidation base with cyclic amino group and a coupling agent | KRT18, AOC1, DPYD | SYK 3070/4885AR 2656/4885ELANE 3130/4885 |
| US-20160303138-A1 | Combination Therapy Of Substituted Oxazolidinones | P2RY12, P2RY11, P2RY1 | SYK 83/4885AR 3011/4885ELANE 1577/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | SYK 9/4885AR 2148/4885ELANE 4810/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | SYK 11/4885AR 1705/4885ELANE 4532/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | SYK 9/4885AR 1845/4885ELANE 4571/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | SYK 9/4885AR 1845/4885ELANE 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.